Arrowgrass Capital Partners (US)’s Clovis Oncology, Inc. CLVS Stock Holding History

Arrowgrass Capital Partners (US)’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-174,569	Closed	-$16.3M	–	630
2017 Q2	$16.3M	Buy	+174,569	New	+$10.7M	0.12%	216
2016 Q2	–	Sell	-50,000	Closed	-$960K	–	456
2016 Q1	$960K	Buy	+50,000	New	+$1.06M	0.01%	320
2015 Q3	–	Sell	-22,500	Closed	-$1.98M	–	543
2015 Q2	$1.98M	Buy	+22,500	New	+$1.93M	0.03%	336
2015 Q1	–	Sell	-15,000	Closed	-$840K	–	546
2014 Q4	$840K	Sell	15,000 -5,000	-25%	-$263K	0.01%	317
2014 Q3	$907K	Buy	+20,000	New	+$835K	0.02%	240

Other funds holding CLVS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Arrowgrass Capital Partners (US)'s CLVS Position: Q3 2017 in Review

Arrowgrass Capital Partners (US) sold out of Clovis Oncology, Inc. (CLVS) in Q3 2017, closing a stake of 174,569 shares — an estimated $16.3M sold.

Arrowgrass Capital Partners (US) first reported a position in CLVS in Q3 2014 and held it in 5 quarters. The position peaked at $16.3M in Q2 2017. 255 funds tracked by Wall St. Rank hold CLVS as of Q3 2017.

Arrowgrass Capital Partners (US) reported no remaining Clovis Oncology, Inc. position as of Q3 2017 after selling out during the quarter.
Arrowgrass Capital Partners (US) sold 174,569 Clovis Oncology, Inc. shares in Q3 2017, an estimated $16.3M.
Arrowgrass Capital Partners (US) first reported a position in Clovis Oncology, Inc. in Q3 2014 and held it in 5 quarters.
Arrowgrass Capital Partners (US)'s Clovis Oncology, Inc. position peaked at $16.3M in Q2 2017.
255 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2017.

Based on Arrowgrass Capital Partners (US)'s 13F filing for Q3 2017, filed 14 Nov 2017.